



✓

✓



✓

✓

✓

✓

✓

1.	82273816	LSD1/MAO	LSD1/Topo
I			2023/01-2026/12 52
2.	-	U1704184	LSD1
		2018/01-2020/12 51	
3.	81402793	LSD1/HDACs	
	2015/01-2017/12 23		
4.		2023/01-2025/12 25	
5.	LSD1	PROTACs	
	182102310124	2018.01-2020.12 10	

1. **Yingchao Duan**, Tong Yu, Linfeng Jin, Shaojie Zhang, Xiaojing Shi, Yizhe Zhang, Nanqian Zhou, Yongtao Xu, Wenfeng Lu, Huimin Zhou, Huijuan Zhu, Suping Bai a, Kua Hu, Yuan Yuan Guan, Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors. *Eur. J. Med. Chem.*, **2023**, 254, 115367.
2. Yuan Zhao, Yuan-Yuan Guan, Fang Zhao, Tong Yu, Shao-Jie Zhang, Yi-Zhe Zhang, **Ying-Chao Duan\*\***, Xiao-Li Zhou\*, Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs, *Eur. J. Med. Chem.*, **2022**, 231, 114144.
3. Xiao-Li Zhou, Fang Zhao, Yong-Tao Xu, Yuan-Yuan Guan, Tong Yu, Yi-Zhe Zhang, **Ying-Chao Duan\*\***, Yuan Zhao\*, A comprehensive review of BET-targeting PROTACs for cancer therapy, *Bioorg. Med. Chem.*, **2022**, 73, 117033.
4. **Ying-Chao Duan\***, Shao-Jie Zhang, Xiao-Jing Shi, Lin-Feng Jin, Tong Yu, Yu Song, Yuan-Yuan Guan, Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy, *Eur. J. Med. Chem.*, **2021**, 222, 113588.
5. **Ying-Chao Duan\***, Lin-Feng Jin, Hong-Mei Ren, Shao-Jie Zhang, Yue-Jiao Liu, Yong-Tao Xu, Zi-Hao He, Yu Song, Hang Yuan, Shu-Hui Chen, Yuan-Yuan Guan, Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer, *Eur. J. Med. Chem.*, **2021**, 220, 113453.
6. **Duan Y. C.\***, Ma Y.C, Qin W. P, Ding L. N, Zheng Y. C., Zhu Y.L., Zhai X. Y., Yang J., Ma C. Y., Guan Y. Y.\*, Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment, *Eur. J. Med. Chem.*, **2017**, 140: 392~402.
7. **Duan Y. C.**, Guan Y. Y., Zhai X. Y., Ding L. N., Qin W. P., Shen D. D., Liu X. Q., Sun X. D., Zheng Y. C. Liu H. M., Discovery of resveratrol derivatives as novel LSD1 inhibitors: Design, synthesis and their biological evaluation, *Eur. J. Med. Chem.*, **2017**, 126: 246~258.
8. **Ying-Chao Duan**, Wen-Ping Qin, Feng-Zhi Suo, Xiao-Yu Zhai, Yuan-Yuan Guan, Xiao-Juan Wang, Yi-Chao Zheng, Hong-Min Liu\*, Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy, *Bioorg. Med. Chem.*, **2018**, 26, 6000-6014.
9. **Ying-Chao Duan**, Yuan-Yuan Guan, Wen-Ping Qin, Xiao-Yu Zhai, Bin Yu, Hong-Min Liu, Targeting Brd4 for cancer therapy: inhibitors and degraders, *Med. Chem. Commun.*, **2018**, 9, 1779-1802.
10. Zheng Y. C.(#), **Duan Y. C.(#)**, Ma J. L., Xu R. M., Zi X., Lv W. L., Wang M. M., Ye X. W., Zhu S. Mobley D., Zhu Y. Y., Wang J. W., Li J. F., Wang Z. R., Zhao W., Liu H. M. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth,invasion, and migration, *J. Med. Chem.*, **2013**, 56, 8543~8560.

- ✓ 1. LSD1/HDACs 2022.07  
ZL 202010516850.2
- ✓ 2. LSD1/HDAC 2022.05 ZL 202110766449.9  
2- -4-(1H- -3- )
- ✓ 3. LSD1 2017.10 ZL 201610357637.5.
- ✓ 4. 2020.03 ZL201710750072.1  
LSD1
- ✓ 5. LSD1 2020.03 ZL201710750071.7  
2- -4-